AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP, a shareholder rights litigation firm, is reminding Aardvark Therapeutics (NASDAQ: AARD) investors of a pending securities fraud class action and soliciting lead plaintiff candidates ahead of an October 13, 2026 deadline. The complaint alleges Aardvark made false and misleading statements about the safety profile and clinical and commercial prospects of its ARD-101 drug candidate, with the class period running from the February 13, 2025 IPO through May 14, 2026.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.